Drug intelligence / Profile preview

ammonium chloride formulation

Development stage
Unknown
Administration
Oral
01

Overview

A sustained-release nutritional supplement containing ammonium chloride and vitamin D. It is being investigated for its potential antiviral effects, specifically aiming to reduce viral load in adult patients with mild or moderate respiratory RNA virus infections, such as COVID-19 and seasonal influenza.

Other names
sustained-release ammonium chloride formulation with vitamin D

Beyond the preview

Go deeper on ammonium chloride formulation.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on ammonium chloride formulation.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call